LRRN1 and neoplasm: Even at relatively low dose (100 μg, twice a week), treatment of N1mAb led to significant suppression of tumor growth of SH-SY5Y/NLRR1 cells, strongly supporting the growth inhibitory effect of N1mAb (Figure 3A).